Charles Rudin, MD, PhD
Chief, Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
Dr. Rudin directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. His laboratory is interested in small cell and non-small cell lung cancers. Some of the strategies the group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus.
Dr. Rudin co-chairs the ECOG Thoracic Core Committee, and is a member of the Intergroup Correlative Sciences Committee, the ASCO Cancer Research Committee, and the NCI Investigational Drug Steering Committee. Dr. Rudin was a standing member of the NIH Clinical Oncology (CONC) Study Section, and has been on the editorial boards of the Journal of Clinical Oncology, Investigational New Drugs, and Cancer Prevention Research. Awards include the Annals of Oncology Prize for the best article on early phase clinical research published in the previous 2 years, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, election to the American Society of Clinical Investigation, and the 2011 AACR Caring for Carcinoid Award.